Fri, Dec 19, 2014, 7:34 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • loriskhireward loriskhireward Dec 1, 2011 3:04 PM Flag

    Short interest = ignorance of health care

    costs of treating c-diff patients, who 20% of the time suffer a recurrence of dreadful episodes of diarrhea...as well as complications such as dehydration, skin breakdown, infection of others in institutional populations, etc. - all reasons for OPTR to garner huge sales and increased usage. The population is aging, not getting younger, and as the >80 population surges, do you think they're going to be getting health care exclusively in their homes?!?? nope - the same acute care, long term acute care, rehab, skilled nursing, long term care and hospice facilities & centers will be caring for them as they do today, only in greater numbers. Patients at other settings who get c-diff usually go to ACUTE CARE (right, doc?), as the symptoms are not manageable in alternate settings - right, doc & proinvestor? or, have you never set foot in an institutional setting, or had a relative you were caring for experience c-diff?

    Overall health care costs are skyrocketing for US health care payers, whether it's Medicare, Medicaid, private insurance or private paying families & patients. Re-hospitalzations and transitioning across multiple institutions are a primary reason, imo, that the elderly do not get better or cured at better rates; it takes a physical AND EMOTIONAL toll on seniors, and they in a lot of cases are COMPROMISED and vulnerable to multiple infections.

    Check out the demographic trends, monitor what is put out regarding exploding cost of care for seniors, then come back & argue that Optimer's Dificid - which cuts recurrence rates for c-diff vs. vanco treatment and is easy to administer - will not play a HUGE part in relieving the dramatically increasing cost of hospitalizations among the elderly, reducing the emotional & physical impact of c-diff on patients & families, and providing hospitals with a better answer to avoiding re-hospitalizations for which they will not be paid.

    Pro, I am certain you have some very strong thoughts on how better to reign in the costs associated with c-diff recurrence & re-hospitalizations in seniors, as well as how to comfort and advise patients & families who might like to try something other than what's been around for years...the FDA felt it necessary to fast-track the drug, right?

    Of course, it's just my opinion and there's a famous quote about those...

 
OPTR
12.780.0000(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.